Table 1.

Studies on sarcopenia in pediatric patients with chronic liver disease.

Author/Year	Patients/number/gender	Age	Method of diagnosis	Evaluation	Clinical outcome
Mangus 201714	ESLD/35/ females 60% Age- and sex-matched healthy controls/35.	Mean 7.8 (range 0•17) yrs.	CT L 2-L3 Psoas muscle area/height. No assessment of muscle function.	Comparison with matched controls.	23% sarcopenia in ESLD vs. controls. Female gender: more fat and less muscle. Age 13•17 yrs, higher prevalence of sarcopenia.
Lurz 201815	ESLD/23/ females 60% Age- and sex-matched healthy controls/46	Mean 0.9 (range 0.5•3.7) yrs.	CT L 3-L4 Psoas muscle area/height. No assessment of muscle function.	Comparison with matched controls.	Psoas muscle area significantly decreased in ESLD children.
Mager 201816	1•8 yrs Post-liver transplantation/41/ females 58%.	0.5•17 years	DEXA No assessment of muscle function.	Skeletal muscle mass z-score < 2.	Sarcopenia in 40% of post liver transplant children.

ESLD, end-stage liver disease., CT, computed tomography, DEXA, dual-energy X-Ray absorptiometry.